Gross Profit Comparison: Ascendis Pharma A/S and Amneal Pharmaceuticals, Inc. Trends

Pharma Giants' Profit Battle: Amneal vs. Ascendis

__timestampAmneal Pharmaceuticals, Inc.Ascendis Pharma A/S
Wednesday, January 1, 201444963400013983000
Thursday, January 1, 20154992260008118000
Friday, January 1, 20165974550004606000
Sunday, January 1, 20175261780001530000
Monday, January 1, 201871640300010581000
Tuesday, January 1, 201935299700013375000
Wednesday, January 1, 20206283930006953000
Friday, January 1, 20217689730004255000
Saturday, January 1, 202278470800039037000
Sunday, January 1, 2023820565000222323000
Monday, January 1, 2024319383000
Loading chart...

In pursuit of knowledge

Gross Profit Trends: Ascendis Pharma A/S vs. Amneal Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. Over the past decade, Amneal Pharmaceuticals, Inc. has consistently outperformed Ascendis Pharma A/S in terms of gross profit. From 2014 to 2023, Amneal's gross profit surged by approximately 82%, peaking in 2023. In contrast, Ascendis Pharma A/S, while showing a significant increase in 2023, experienced a more volatile journey, with a remarkable 5,000% growth from 2014 to 2023. This disparity highlights the different growth trajectories and market strategies of these companies. Amneal's steady climb reflects its robust market presence, while Ascendis's recent spike suggests a breakthrough in its business model. As the pharmaceutical landscape continues to shift, these trends offer valuable insights into the financial health and strategic direction of these industry players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025